 Home > Active Ingredient News > Endocrine System > Microchip's partner submits Chidamide's listing application in Japan and is accepted

Microchip's partner submits Chidamide's listing application in Japan and is accepted

 Last Update: 2021-05-10
 Source: Internet
 Author: User

Tags

benzodiazepines drug class

single cell proteomics

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 28, Microchip released an announcement stating that its partner Huya Bio-International Co.

Chidamide is the world's first subtype-selective histone deacetylase (HDAC) inhibitor and the world's first oral administration approved for the treatment of peripheral T-cell lymphoma and combined endocrine drugs for the treatment of estrogen receptor-positive breast cancer The drug, targeting class I histone deacetylase (HDAC), induces cell cycle arrest, inhibits the expression of a variety of oncogenes, regulates the acetylation of PD-L1, and enhances the activity of immune checkpoint inhibitors.

Peripheral T-cell lymphoma (PTCL) is a group of highly heterogeneous abnormal malignant proliferation of lymphocytes.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.